Effects of artesunate on parasite recrudescence and dormancy in the rodent malaria model Plasmodium vinckei

• Published in: PloS one 2011-10, Vol.6 (10), p.e26689-e26689
• Main Authors: LaCrue, Alexis N, Scheel, Misty, Kennedy, Katherine, Kumar, Nikesh, Kyle, Dennis E
• Format: Article
• Language: English
• Subjects: Analysis; Animals; Antigens; Antimalarials - pharmacology; Artemisinin; Artemisinins - pharmacology; Artesunate; Biology; Clinical trials; Developmental stages; Dihydroartemisinin; Disease Models, Animal; Dormancy; Drug dosages; Drug resistance; Erythrocytes; Failure; Flow cytometry; Health aspects; In vivo methods and tests; Infection; Malaria; Malaria - parasitology; Mice; Parasites; Plasmodium; Plasmodium - drug effects; Plasmodium - physiology; Plasmodium falciparum; Plasmodium vinckei; Studies; Substance abuse treatment; Vector-borne diseases
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0026689

Artemisinin (ART) is the recommended first line therapy for treating uncomplicated and drug-resistant Plasmodium falciparum, the most pathogenic form of malaria. However, treatment failure following ART monotherapy is not uncommon and resistance to this rapidly acting drug has been reported in the Thai-Cambodian border. Recent in vitro studies have shown that following treatment with dihydroartemisinin (DHA), the development of ring-stage parasites is arrested for up to 20 days. These arrested (i.e. dormant) rings could be responsible for the recrudescence of infection that is observed following ART monotherapy. To develop a better understanding of the stage-specific effects of ART and determine if dormancy occurs in vivo, the ART derivative artesunate (AS) was used to treat mice infected with the synchronous rodent malaria parasites P. vinckei petteri (non-lethal) and P. v. vinckei (lethal). Results show that in both the non-lethal and lethal strains, ring-stage parasites are the least susceptible to treatment with AS and that the day of treatment has more of an impact on recrudescence than the total dose administered. Additionally, 24 hrs post-treatment with AS, dormant forms similar in morphology to those seen in vitro were observed. Finally, rate of recrudescence studies suggest that there is a positive correlation between the number of dormant parasites present and when recrudescence occurs in the vertebrate host. Collectively, these data suggest that dormancy occurs in vivo and contributes to recrudescence that is observed following AS treatment. It is possible that this may represent a novel mechanism of parasite survival following treatment with AS.